Significant PFS Improvement with Ibrutinib-Rituximab Compared to Immunochemotherapy in Previously Untreated Patients with Mantle Cell Lymphoma By Ogkologos - October 24, 2025 315 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ENRICH study Source RELATED ARTICLESMORE FROM AUTHOR FDA Approves Gedatolisib with Fulvestrant, With or Without Palbociclib, for HR-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer Potential Role of an Activated Tumour Immune Microenvironment in Predicting Benefit from Atezolizumab for TNBC Perioperative Pembrolizumab Plus Neoadjuvant Chemotherapy Continues to Prolong EFS and OS in Patients with Stage II, IIIA, or IIIB (N2) NSCLC MOST POPULAR News digest – sponge on a string, junk food watershed, prostate... August 1, 2020 Prescribing Exercise as Cancer Treatment: A Conversation with Dr. Kathryn Schmitz November 12, 2019 Avasopasem Shields Normal Cells from Radiation, Helps Kill Cancer Cells June 23, 2021 FDA Approves Daratumumab and Hyaluronidase-fihj With Pomalidomide and Dexamethasone for Multiple... July 14, 2021 Load more HOT NEWS What to Know About Kidney Cancer Genetic Conditions and Genetic Counseling Study Details Long-Term Side Effects of Immune Checkpoint Inhibitors Experimental Treatment Uses Engineered Fat Cells to “Starve” Tumors NHS England change of chief executive – what does it mean...
